Fludrocortisone

證據等級: L5

預測適應症: 10 個

Fludrocortisone: From Adrenocortical Insufficiency to Primary Cutaneous T-Cell Lymphoma

One-Sentence Summary

Fludrocortisone is a synthetic mineralocorticoid conventionally used as replacement therapy for adrenocortical insufficiency (e.g. Addison’s disease) and orthostatic hypotension. The TxGNN model predicts it may be effective for Primary Cutaneous T-Cell Lymphoma, but this direction is currently supported by 0 clinical trials and only 1 literature reference of unconfirmed relevance.

Note: The Evidence Pack does not itself confirm the original indication (original_indications and original_moa are both unavailable) — the description above is based on general pharmacological knowledge of fludrocortisone, not on data extracted from this Evidence Pack.

Quick Overview

Item	Content
Original Indication	Not available in Evidence Pack (mineralocorticoid class, general reference only)
Predicted New Indication	Primary Cutaneous T-Cell Lymphoma
TxGNN Prediction Score	99.58%
Evidence Level	L5
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this candidate (Data Gap DG002). Based on general pharmacological knowledge, fludrocortisone is a synthetic mineralocorticoid within the corticosteroid class, and its efficacy in adrenocortical insufficiency is well established.

Corticosteroids as a class have anti-inflammatory and immunosuppressive properties, and some corticosteroids (typically glucocorticoids, both topical and systemic) are used adjunctively in the management of cutaneous T-cell lymphoma symptoms. This provides a plausible, but unconfirmed, mechanistic rationale for the TxGNN prediction linking fludrocortisone to primary cutaneous T-cell lymphoma. However, fludrocortisone’s dominant pharmacology is mineralocorticoid (salt/water regulation) rather than glucocorticoid/immunomodulatory activity, so this mechanistic link should be treated as speculative pending confirmed MOA data and dedicated study.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6028675	1967	Unclassified (classification pending)	Archives of Dermatology	Title only (“Pathergic granulomatosis”); no abstract available and relevance to primary cutaneous T-cell lymphoma has not yet been verified

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. No key warnings, contraindications, or drug interaction data were available in this Evidence Pack (DDI query returned no results).

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN prediction score, there are no clinical trials and only a single literature reference whose relevance to primary cutaneous T-cell lymphoma is unconfirmed (abstract unavailable, classification pending) — the evidence base is currently insufficient to support progression.

To proceed, the following is needed:

Confirmed mechanism of action (MOA) data for fludrocortisone (DG002)
TGA/TFDA-approved Product Information covering warnings and contraindications (DG001)
Verification of the PMID 6028675 abstract and its actual relevance to CTCL
Dedicated preclinical or mechanistic studies linking mineralocorticoid activity to CTCL pathophysiology
Confirmation of original approved indication(s) for fludrocortisone in the target jurisdiction
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.